Clinical Report: MMF Shows Promise in Juvenile Scleroderma
Overview
Mycophenolate mofetil (MMF) demonstrated comparable effectiveness to methotrexate (MTX) in reducing disease activity in juvenile localized scleroderma (JLS) based on a retrospective study of 114 patients, while causing significantly fewer adverse effects. This study suggests MMF as a potential first-line treatment option for JLS, pending further validation.
Background
Juvenile localized scleroderma is a potentially disabling condition that can significantly impact a child's quality of life. Current treatment options primarily include methotrexate, but its associated adverse effects, such as nausea and fatigue, can limit its use. Understanding alternative therapies like MMF is crucial for optimizing patient outcomes.
Data Highlights
| Treatment | Inactive Disease Status | Nausea Rate | Fatigue Rate |
|---|---|---|---|
| MTX (n=68) | Yes | 60% | 47% |
| MMF (n=28) | Yes | 7% | 11% |
Key Findings
- MMF and MTX achieved similar rates of inactive disease status within 12 months.
- Patients on MTX experienced significantly higher rates of nausea (60% vs 7%) and fatigue (47% vs 11%) compared to those on MMF.
- 25% of patients experienced disease flare, with no significant differences in flare-free survival between treatment groups.
- Longitudinal analysis indicated stable disease activity post-corticosteroid discontinuation across all groups.
- MMF was often initiated after longer disease duration or due to MTX intolerance, which may affect comparative outcomes. Limitations include the retrospective design and unequal treatment group sizes.
Clinical Implications
The findings support the consideration of MMF as a first-line treatment for juvenile localized scleroderma, particularly for patients who experience adverse effects from methotrexate. Clinicians should weigh the benefits of reduced adverse effects against the treatment history and disease characteristics of individual patients. Further studies are needed to validate these findings.
Conclusion
This study highlights the potential of MMF as an effective and better-tolerated alternative to methotrexate for treating juvenile localized scleroderma. Further prospective studies are needed to confirm these findings and guide future treatment recommendations.
References
- Elena C. de Rosas, et al., JAMA Dermatology, 2026 -- Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma
- European Dermatology Forum, 2024 -- European Dermatology Guidelines
- Bone Marrow Transplantation — Highlights from the 46th Annual Conference of the European Society for Blood and Marrow Transplantation: Award Recipients (O001-O009)
- Clinical Rheumatology — Management of refractory juvenile dermatomyositis using tacrolimus
- Clinical Rheumatology — Effects of Supernatants from Type I Collagen-Stimulated PBMC Cultures in Patients with Cutaneous Systemic Sclerosis Compared to Localized Scleroderma on MMP-1 Suppression in Fibroblasts
- Clinical Rheumatology — The Role of CAR-T Cell Therapy in Systemic Sclerosis Management
- Title:
- Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma | Dermatology | JAMA Dermatology | JAMA Network
- Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center | Pediatric Rheumatology | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
